We write complex pharmaceutical documents with purpose-built AI.
We produce them up to 6× faster than a traditional consultancy, at a competitive price.
Subject-matter experts shouldn’t be writing and formatting templated documents. We give them that time back for the science.
Our experts come from
Our in-house software handles the drafting, source-tracing and formatting. Senior reviewers who have filed submissions themselves use it to write your documents.
AcribaWord is our own editor. It reads your reports and the applicable guidelines. Then it produces a consistent, submission-ready draft for our reviewers to work on.
Our experts work inside AcribaWord to bring the document to submission quality. It runs QC on the reports for them, so their time goes to content and strategy.
We delivered an IND update in thirty days: fifteen documents, including M2.4, M2.5 and M2.7 summaries written from scratch. The nearest competing quote was three months or more, at a higher price. A former CSO who has filed multiple INDs reviewed every page.
Generic AI tools can’t ingest the inputs of a drug program. One program is dozens of reports and hundreds of pages, dense with tables and figures. They can draft a simple document. They cannot handle the formatting and cross-referencing that a regulatory or medical dossier requires.
Note: AcribaWord is also available as a standalone product. Enquire about licensing →
Request a walkthrough →We work with experts across most modalities and therapeutic areas. We have a partnership with CXO Swiss, a network of Swiss pharmaceutical leaders across clinical, regulatory, preclinical, CMC and finance.